Literature DB >> 10548357

Comparison of 200 mg cimetidine with multiple doses of antacid on extent and duration of rise in gastric pH in volunteers.

A B Thomson1, P Kirdeikis, L Zuk.   

Abstract

The effects on gastric pH of a single administration of 200 mg cimetidine (Tagamet HB) were compared to multiple doses of a liquid antacid (Mylanta) using a pH microelectrode. Gastric pH was monitored for 8 hr in 20 normal fasting volunteers in a crossover design to compare Tagamet HB (two 100-mg tablets administered as a single dose) with Mylanta Suspension, an initial 17.5-ml dose of antacid with additional doses given when gastric pH fell below 3.5. Both treatments increased the pH above 3.5 during the first hour following treatment, with Mylanta being more effective than Tagamet HB. Interestingly, to sustain the reduction in acidity during this 1-hr interval, a mean of 2.45 doses of antacid were administered. Although multiple doses of Mylanta kept the pH above 3.5 (for at least 25% of the time) for the first 4 hr, the single administration of 200 mg of Tagamet HB maintained gastric pH above 3.5 (greater than 25% of time) for the full 8 hr of the study. Compared to Mylanta, the percent of time gastric pH was >3.5 was significantly higher with Tagamet HB during the 3rd to 8th hour after dosing. This study demonstrates that 200 mg of cimetidine administered as Tagamet HB is significantly more effective and has a much longer duration of action in raising gastric pH >3.5 than six doses of Mylanta.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10548357     DOI: 10.1023/a:1026678503604

Source DB:  PubMed          Journal:  Dig Dis Sci        ISSN: 0163-2116            Impact factor:   3.199


  6 in total

1.  The milk alkali syndrome: a study of the acute disorder with comments on the development of the chronic condition.

Authors:  D E McMillan; R B Freeman
Journal:  Medicine (Baltimore)       Date:  1965-11       Impact factor: 1.889

2.  Acute effects of antacids on gastric juice components in duodenal ulcer patients.

Authors:  R Weberg; K Berstad; A Berstad
Journal:  Eur J Clin Invest       Date:  1990-10       Impact factor: 4.686

Review 3.  The milk-alkali syndrome: current concepts.

Authors:  E S Orwoll
Journal:  Ann Intern Med       Date:  1982-08       Impact factor: 25.391

4.  A unique postmarket outpatient surveillance program of cimetidine: report on phase II and final summary.

Authors:  T J Humphries; R M Myerson; L M Gifford; M E Aeugle; M E Josie; S L Wood; P J Tannenbaum
Journal:  Am J Gastroenterol       Date:  1984-08       Impact factor: 10.864

Review 5.  Pharmacological management of patients with peptic ulcer disease: prospects for the late 1980's.

Authors:  A B Thomson; V Mahachai
Journal:  Clin Invest Med       Date:  1987-05       Impact factor: 0.825

6.  Post-marketing surveillance of the safety of cimetidine: twelve-month morbidity report.

Authors:  D G Colin Jones; M J Langman; D H Lawson; M P Vessey
Journal:  Q J Med       Date:  1985-03
  6 in total
  1 in total

1.  Crystal structure transformations and dissolution studies of cimetidine-piroxicam coprecipitates and physical mixtures.

Authors:  Vimon Tantishaiyakul; Sarunyoo Songkro; Krit Suknuntha; Pattakarn Permkum; Pattawee Pipatwarakul
Journal:  AAPS PharmSciTech       Date:  2009-06-12       Impact factor: 3.246

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.